TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

Shilong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.